Vanguard Group Inc Durect Corp Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.43 - $5.9 $96,922 - $1.33 Million	225,402 Added 2.25%	10,243,592 $5.92 Million
Q2 2022 Aug 12, 2022	SELL	$0.38 - $0.64 $481,689 - $811,265	-1,267,603 Reduced 11.23%	10,018,190 $4.79 Million
Q1 2022 May 13, 2022	SELL	$0.55 - $0.98 $5,602 - $9,982	-10,186 Reduced 0.09%	11,285,793 $7.56 Million
Q4 2021 Feb 14, 2022	SELL	$0.9 - $1.31 $115,361 - $167,914	-128,179 Reduced 1.12%	11,295,979 $11.1 Million
Q3 2021 Nov 12, 2021	BUY	$1.21 - $1.61 $64,726 - $86,123	53,493 Added 0.47%	11,424,158 $14.6 Million
Q2 2021 Aug 13, 2021	BUY	$1.6 - $2.02 $18.2 Million - $23 Million	11,370,665 New	11,370,665 $18.5 Million

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $189M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.